

First Quarter 2020 Update

Dear Friend of Navigation Sciences,

I hope you are safe and managing through these difficult times. We would like to provide you with an update on Navigation Sciences' progress despite the challenges we are all facing in the wake of the novel coronavirus pandemic. We recently raised another \$250,000 in our seed round, bringing the total capital raise to date to \$1.5 million.

These funds will support an Investigational Device Exemption (IDE) submission to begin first-in-man studies with our revolutionary navigation system for lung tumor localization and safe oncological resection. The planned clinical trial, in 25 patients, will be a major value inflection point for the company.

The study will evaluate the system's safety, and its ability to identify and remove tumors minimally invasively with appropriate margins, as well as provide an initial opportunity to test the technology's economic value proposition of improved surgical workflow and reduced length of stay. The surgeries will be conducted at Brigham and Women's Hospital by Scott Swanson, M.D., Director of Minimally Invasive Surgery at the Hospital and Associate Chief of Surgery at Dana Farber Cancer Center.

We expect to be able to begin the trial in the summer or fall following FDA review of the IDE and Institutional Review Board (IRB) approval at the hospital. Based on the current trajectory of the novel coronavirus in Boston, we are hopeful that non-emergency surgeries will resume by then. Navigation is fortunate that to this point our development activities have been largely unaffected by the pandemic. We have been able to have our team and advisors work remotely. Currently, we are focused on completing several pre-IDE submission activities in preparation for the filing in the coming weeks.

Stay well. Thank you again for your interest in Navigation Sciences.

Sincerely,

Alan Lucas

CEO